Norris Perne & French LLP MI increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 1.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 102,813 shares of the medical research company’s stock after acquiring an additional 1,267 shares during the quarter. Charles River Laboratories International comprises 1.8% of Norris Perne & French LLP MI’s investment portfolio, making the stock its 18th biggest position. Norris Perne & French LLP MI owned about 0.20% of Charles River Laboratories International worth $21,616,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC purchased a new position in Charles River Laboratories International during the fourth quarter worth about $298,877,000. Price T Rowe Associates Inc. MD grew its position in Charles River Laboratories International by 35.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,506,293 shares of the medical research company’s stock worth $505,821,000 after acquiring an additional 653,790 shares during the period. Norges Bank acquired a new stake in Charles River Laboratories International during the fourth quarter worth $97,675,000. Southpoint Capital Advisors LP purchased a new stake in Charles River Laboratories International in the first quarter valued at $80,728,000. Finally, Marshall Wace LLP lifted its stake in shares of Charles River Laboratories International by 57.4% in the 4th quarter. Marshall Wace LLP now owns 874,773 shares of the medical research company’s stock valued at $190,613,000 after purchasing an additional 319,095 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Insider Buying and Selling at Charles River Laboratories International
In related news, VP William D. Barbo sold 5,763 shares of Charles River Laboratories International stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total transaction of $1,251,954.12. Following the sale, the vice president now directly owns 3,592 shares in the company, valued at approximately $780,326.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Charles River Laboratories International news, VP William D. Barbo sold 5,763 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $217.24, for a total value of $1,251,954.12. Following the completion of the sale, the vice president now owns 3,592 shares in the company, valued at $780,326.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard F. Wallman bought 1,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $198,790. The disclosure for this purchase can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 over the last three months. Insiders own 1.30% of the company’s stock.
Charles River Laboratories International Stock Down 1.0 %
NYSE CRL traded down $1.92 on Wednesday, hitting $192.52. 156,849 shares of the stock were exchanged, compared to its average volume of 522,864. Charles River Laboratories International, Inc. has a fifty-two week low of $181.22 and a fifty-two week high of $262.00. The company has a 50-day moving average price of $205.42 and a 200-day moving average price of $201.77. The company has a market cap of $9.87 billion, a PE ratio of 20.62, a PEG ratio of 1.77 and a beta of 1.33. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.82.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, beating the consensus estimate of $2.63 by $0.06. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion. Charles River Laboratories International had a return on equity of 18.99% and a net margin of 11.58%. Charles River Laboratories International’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.77 earnings per share. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.49 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently issued reports on the stock. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $267.00 to $256.00 and set an “outperform” rating on the stock in a report on Friday, September 22nd. Bank of America decreased their price objective on shares of Charles River Laboratories International from $245.00 to $230.00 in a report on Friday, September 22nd. TD Cowen dropped their target price on shares of Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating for the company in a report on Monday. Wells Fargo & Company decreased their price target on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a research note on Friday, September 22nd. Finally, StockNews.com downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus price target of $237.09.
Get Our Latest Report on Charles River Laboratories International
About Charles River Laboratories International
(Free Report)
Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Charles River Laboratories International, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Charles River Laboratories International wasn’t on the list.
While Charles River Laboratories International currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Source link
credite